Literature DB >> 19962485

Usefulness of early diastolic mitral annular velocity to predict plasma levels of brain natriuretic peptide and transient heart failure development after device closure of atrial septal defect.

Satoshi Masutani1, Mio Taketazu, Chihiro Mihara, Yuko Mimura, Hirotaka Ishido, Tamotsu Matsunaga, Toshiki Kobayashi, Hideaki Senzaki.   

Abstract

Device closure of atrial septal defect (ASD) is sometimes followed by elevation of plasma brain natriuretic peptide (BNP), a marker of heart failure, and progression to heart failure. This study tested the hypothesis that the underlying diastolic dysfunction, assessed on tissue Doppler images (TDI) before device closure, can predict BNP level after ASD closure. The study subjects were 39 consecutive patients (age 27.5 +/- 16.3 years, range 5 to 63) who underwent device closure for ASD. Echocardiographic evaluation using TDI and 2-dimensional and pulse wave Doppler were performed, together with plasma BNP measurement 1 day before and 2 days after ASD closure. Before ASD closure, an age-dependent decrease was noted in left ventricular relaxation, assessed by early diastolic mitral annular velocity. ASD closure resulted in a decrease in early diastolic mitral annular velocity (from 14.7 to 12.3 cm/s, p <0.05) despite an increase in the left ventricular dimension (84% to 92% vs normal, p <0.05). These changes were associated with a parallel increase in BNP (17.9 to 48.4 pg/ml, p <0.05). Stepwise multivariate linear regression identified early diastolic mitral annular velocity before ASD closure and age as independent predictors of BNP levels after ASD closure (p <0.05). Consistent with this result, 2 patients with the lowest early diastolic mitral annular velocity developed exertional dyspnea after the procedure. In conclusion, our results indicate that TDI measurements could be useful to detect underlying diastolic dysfunction that can potentially cause heart failure after ASD closure and emphasize the importance of ASD closure at a young age before impairment of left ventricular relaxation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962485     DOI: 10.1016/j.amjcard.2009.07.058

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Assessment of ventricular relaxation and stiffness using early diastolic mitral annular and inflow velocities in pediatric patients with heart disease.

Authors:  Satoshi Masutani; Hirofumi Saiki; Clara Kurishima; Seiko Kuwata; Masanori Tamura; Hideaki Senzaki
Journal:  Heart Vessels       Date:  2014-11       Impact factor: 2.037

2.  Effects of age on hemodynamic changes after transcatheter closure of atrial septal defect: importance of ventricular diastolic function.

Authors:  Satoshi Masutani; Mio Taketazu; Hirotaka Ishido; Yoichi Iwamoto; Shigeki Yoshiba; Tamotsu Matsunaga; Toshiki Kobayashi; Hideaki Senzaki
Journal:  Heart Vessels       Date:  2011-03-18       Impact factor: 2.037

3.  Changes in Plasma Atrial and Brain Natriuretic Peptide Levels in Children Undergoing Surgical Isolated Atrial Septal Defect Closure.

Authors:  Yuki Nakamura; Ikuo Hagino; Mitsuru Aoki; Kouji Higashi; Hiromichi Nakajima
Journal:  Pediatr Cardiol       Date:  2015-03-14       Impact factor: 1.655

Review 4.  Transcatheter closure of secundum atrial septal defect.

Authors:  Hideto Shimpo; Reina Hojo; Maeshiro Ryo; Takeshi Konuma; Hironori Tempaku
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-06-18

Review 5.  Atrial septal defect and exercise capacity: value of cardio-pulmonary exercise test in assessment and follow-up.

Authors:  Pascal Amedro; Sophie Guillaumont; Charlene Bredy; Stefan Matecki; Arthur Gavotto
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

6.  Effectiveness and Safety of Transcatheter Atrial Septal Defect Closure in Adults with Systemic Essential Hypertension.

Authors:  Iwona Świątkiewicz; Łukasz Bednarczyk; Michał Kasprzak; Ewa Laskowska; Marek Woźnicki
Journal:  J Clin Med       Date:  2022-02-13       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.